The U.S. Food and Drug Administration (FDA) Advisory Committee voted 16-1 in favor of passing Alkermes’ schizophrenia and bipolar disorder treatment drug (AKMS 3831). FDA members voiced concern about the potentially addictive qualities of the drug, as it contains an opioid antagonist paired with an already established schizophrenia medication, Eli Lilly. The Irish drug manufacturer claims that with proper package labelling, the issue could be circumvented. The drug will be further decided on November 15th, 2020.
Read more here.